SOURCE: CDEX Inc.

CDEX Inc.

April 12, 2010 09:15 ET

Medication Safety and Narcotic Diversion Prevention Equipment Showcased by CDEX at HCP

TUCSON, AZ--(Marketwire - April 12, 2010) -  CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces demonstration of its ValiMed™ Medication Validation System (MVS) to Directors of Pharmacy at the Health Connect Partners (HCP) Reverse Expo in San Diego, CA on April 12-14. Studies worldwide continue to show unacceptable frequency of mistakes in the compounding of high-risk medications resulting in substantial harm to patients and economic loss to hospitals. In an 18-month University of Michigan Health System study, ValiMed identified 5 major medical errors (see http://www.ns.umich.edu/htdocs/releases/story.php?id=6255). ValiMed MVS is used to validate the compounding of high-risk liquid medications in a pharmacy setting and also as a verification and trending program to reduce the diversion of return narcotics in hospitals and other healthcare facilities.

"ValiMed MVS is another arrow in the quiver of pharmacy directors who have patient safety as one of their top priorities," said Greg Firmbach, CDEX President. "ValiMed MVS provides a technological safety net in the compounding of high risk medications and the 'Quality and Quantity' tools necessary to identify and prevent narcotic diversion."

"HCP is a unique venue allowing CDEX to talk one-on-one with hospital Pharmacy Directors about patient safety," continued Firmbach. "During the three-day event, CDEX's three attending employees will have the potential of making over 90 quality presentations to hospital decision makers as well as networking with the over 200 hospital directors attending. This type of show fits perfectly into our strategic mix of marketing efforts designed to place at least one ValiMed MVS in every major hospital."

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ MVS product line provides life-saving validation of high-risk medications and helps prevent diversion of returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Greg Firmbach at greg.firmbach@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information